23 October 2008 - GlaxoSmithKline (GSK) announced that alli ® (orlistat 60mg) has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) as a non-prescription product. As a result, approval of alli (orlistat 60mg)could be granted by the end of the year across all 27 EU member countries with an anticipated launch in 2009 as the first licensed weight loss treatment available without a prescription. The product would be indicated for adults who are overweight and have a body mass index (BMI) of 28 or more... GlaxoSmithKline's Press Release -
Thursday, October 23, 2008
GlaxoSmithKline : positive CHMP opinion for new non-prescription weight loss treatment – alli® – to help in the fight against obesity across Europe
23 October 2008 - GlaxoSmithKline (GSK) announced that alli ® (orlistat 60mg) has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) as a non-prescription product. As a result, approval of alli (orlistat 60mg)could be granted by the end of the year across all 27 EU member countries with an anticipated launch in 2009 as the first licensed weight loss treatment available without a prescription. The product would be indicated for adults who are overweight and have a body mass index (BMI) of 28 or more... GlaxoSmithKline's Press Release -
